|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Peginterferon alfa-2a (PEG-IFN) treatment stopping rules in chronic hepatitis B (CHB) are clinically desirable.
|
30865588 |
2019 |
|
Hepatitis B, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results can serve as a basis for improving dosing regimens of PEG-IFN alfa-2a in adult patients with chronic hepatitis B or C infection.
|
30179597 |
2018 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the efficacy of combination therapy with lamivudine or tenofovir and pegylated interferon (PEG-IFN) has been reported in patients with chronic hepatitis B (CHB), the long-term effect of the combination based on the observation of clinical course remains to be clarified.
|
29438098 |
2018 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to evaluate the relationship between interleukin-21 (IL-21) and interleukin-21 receptor (IL-21R) polymorphisms and the response to peginterferon alfa (PEG-IFN α) therapy in HBeAg-positive chronic hepatitis B (CHB) patients.A total of 143 HBeAg-positive CHB patients treated for 48 weeks with PEG-IFN α and followed up for 24 weeks post-treatment were retrospectively evaluated.
|
29879024 |
2018 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
We, herein, reported two child-bearing women with chronic hepatitis B (HB) infection who used pegylated interferon alfa 2b (PEG IFNα 2b) in first trimester unintentionally.
|
27125766 |
2017 |
|
Hepatitis B, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association of polymorphisms in key Th-17 immune response genes with HBeAg-positive chronic hepatitis B susceptibility and response to PEG-IFNa-2α.
|
28595093 |
2017 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate possible involvement of estrogen receptor α (ESR1) in responding to pegylated interferon alpha-2a (PEG IFNα-2a) therapy in chronic hepatitis B (CHB) patients.
|
26485345 |
2016 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The treatment of patients affected by active chronic hepatitis B (CHB) could be performed using a finite-time therapy with pegylated-interferon alpha (PEG-IFN) or indefinite time treatment with nucleos(t)ide analogues (NAs).
|
27017932 |
2016 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment options for patients with chronic hepatitis B (CHB) and hepatitis B e antigen (HBeAg)-negative are pegylated interferon alfa-2a (PEG-IFN) for 48 weeks or nucleos(t)ide analogues (NAs).
|
27793564 |
2016 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of quantitative serum hepatitis B core-related antigen (HBcrAg) in patients with chronic hepatitis B (CHB) receiving pegylated interferon (PEG-IFN) is unclear.
|
26678018 |
2016 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The single nucleotide polymorphism (SNP) ss469415590 in the interferon lambda-4 (IFNL4) gene has recently been reported to have an association with treatment response in chronic hepatitis C. However, any importance of the SNP in association with response to pegylated interferon (PEG-IFN) therapy in patients with chronic hepatitis B (CHB) is unclear.
|
26225703 |
2015 |
|
Hepatitis B, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon.
|
25060765 |
2015 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate whether IL28B polymorphisms could affect the treatment response to peginterferon alpha (PEG-IFN) in chronic hepatitis B (CHB) patients in the Chinese Han population.
|
24517415 |
2015 |
|
Hepatitis B, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate whether IPS1 polymorphisms affect peginterferon alpha (PEG-IFN) efficacy in chronic hepatitis B (CHB) patients using a tag- single nucleotide polymorphism (SNP) approach.
|
25640825 |
2015 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the predictive effect of baseline hepatitis B surface antigen (HBsAg) on response to pegylated interferon (PEG-IFN)-α2b in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients.
|
25009392 |
2014 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
More prospective studies including large cohorts are needed to determine the possible association between IL28B genetic polymorphism and the outcome of interferon or PEG-IFN treatment for chronic hepatitis B.
|
25232239 |
2014 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several factors have been related to response to pegylated interferon (PEG-IFN) in chronic hepatitis B (CHB).
|
24296674 |
2014 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Peginterferon α (PEG-IFN), which includes PEG-IFN α-2a (Pegasys) and PEG-IFN α-2b (Peg-Intron), can be used to treat patients with chronic hepatitis B (CHB) infection.
|
24738850 |
2014 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Products that are currently used in the treatment of chronic hepatitis B include interferon-alpha (IFNa: standard or pegylated) (PEG-IFNa) and nucleos(t)ide analogues (NAs).
|
23286859 |
2013 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
On-treatment levels of hepatitis B surface antigen (HBsAg) may predict response to peginterferon (PEG-IFN) therapy in chronic hepatitis B (CHB), but previously proposed prediction rules have shown limited external validity.
|
23553752 |
2013 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The study aimed to investigate the efficacy and safety of peginterferon α-2a (PEG IFNα-2a) in combination with lamivudine or adefovir in the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB).
|
23615131 |
2013 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is lack of a practical biomarker to predict sustained virological response (SVR) in chronic hepatitis B (CHB) patients undergoing peginterferon alfa-2a (PEG-IFN).
|
24124595 |
2013 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Polymorphisms near IL28B are independently associated with serologic response to PEG-IFN in patients with HBeAg-positive chronic hepatitis B.
|
22108195 |
2012 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Peginterferon (PEG-IFN) treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) results in HBeAg loss in 30% of patients, but clearance of hepatitis B virus (HBV) DNA and hepatitis B surface antigen (HBsAg) from serum is less often achieved.
|
22307831 |
2012 |
|
Hepatitis B, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
On-treatment decline of serum hepatitis B surface antigen (HBsAg) may reflect the immunomodulatory effect of pegylated interferon (PEG-IFN) for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB).
|
22267464 |
2012 |